These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 36995071)

  • 1. Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.
    Islam MR; Osman OI; Hassan WMI
    J Biomol Struct Dyn; 2024; 42(1):82-100. PubMed ID: 36995071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.
    Egbuna C; Patrick-Iwuanyanwu KC; Onyeike EN; Khan J; Alshehri B
    J Biomol Struct Dyn; 2022; 40(22):12248-12259. PubMed ID: 34486940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore-Based Virtual Screening, Quantum Mechanics Calculations, and Molecular Dynamics Simulation Approaches Identified Potential Natural Antiviral Drug Candidates against MERS-CoV S1-NTD.
    Bouback TA; Pokhrel S; Albeshri A; Aljohani AM; Samad A; Alam R; Hossen MS; Al-Ghamdi K; Talukder MEK; Ahammad F; Qadri I; Simal-Gandara J
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Modeling Studies of
    Ghosh S; Keretsu S; Cho SJ
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
    Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering the mechanism of HM43239 inhibiting the mutant F691L resistant to gilteritinib in FMS-like tyrosine kinase 3.
    Wang Z; An Y; Wang J; Lu J
    J Biomol Struct Dyn; 2024 Jul; 42(11):5817-5826. PubMed ID: 37382586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.
    Ke YY; Singh VK; Coumar MS; Hsu YC; Wang WC; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Shih C; Hsieh HP
    Sci Rep; 2015 Jun; 5():11702. PubMed ID: 26118648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.
    Hu S; Liu J; Chen S; Gao J; Zhou Y; Liu T; Dong X
    Biol Pharm Bull; 2021; 44(12):1872-1877. PubMed ID: 34853270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
    Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
    Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore-based virtual screening, molecular docking, and molecular dynamics studies for the discovery of novel FLT3 inhibitors.
    Ouassaf M; Daoui O; Alam S; Elkhattabi S; Belaidi S; Chtita S
    J Biomol Struct Dyn; 2023; 41(16):7712-7724. PubMed ID: 36106982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computer-guided design, synthesis, and biological evaluation of quinoxalinebisarylureas as FLT3 inhibitors.
    Göring S; Bensinger D; Naumann EC; Schmidt B
    ChemMedChem; 2015 Mar; 10(3):511-22. PubMed ID: 25677073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.
    Al-Subaie AM; Kamaraj B
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in FLT3 inhibitors for acute myeloid leukemia.
    Tong L; Li X; Hu Y; Liu T
    Future Med Chem; 2020 May; 12(10):961-981. PubMed ID: 32314599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia.
    Yen SC; Wu YW; Huang CC; Chao MW; Tu HJ; Chen LC; Lin TE; Sung TY; Tseng HJ; Chu JC; Huang WJ; Yang CR; HuangFu WC; Pan SL; Hsu KC
    Phytomedicine; 2022 Jun; 100():154061. PubMed ID: 35364561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
    Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
    Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
    [No Abstract]   [Full Text] [Related]  

  • 16. Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia.
    Bultum LE; Tolossa GB; Lee D
    PLoS One; 2022; 17(7):e0270050. PubMed ID: 35895695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computer-aided anti-cancer drug discovery of EGFR protein based on virtual screening of drug bank, ADMET, docking, DFT and molecular dynamic simulation studies.
    Roney M; Dubey A; Hassan Nasir M; Tufail A; Tajuddin SN; Mohd Aluwi MFF; Huq AM
    J Biomol Struct Dyn; 2024 Nov; 42(18):9662-9677. PubMed ID: 37676262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Solana-Altabella A; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):1-18. PubMed ID: 35076348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 inhibitor design using molecular docking based virtual screening for acute myeloid leukemia.
    Gokhale P; Chauhan APS; Arora A; Khandekar N; Nayarisseri A; Singh SK
    Bioinformation; 2019; 15(2):104-115. PubMed ID: 31435156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.